Corindus Is to showcase the CorPath GRX system at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2019; 25–29 September, San Francisco, USA). CorPath GRX is the only US Food and Drug Administration (FDA) cleared and CE-marked medical device for robotic-assisted vascular interventions.
The company says that attendees will be able to gain hands-on experience with CorPath GRX in an advanced simulation at their booth, and the next set of automated movements in the technIQ™ Series will be available for demonstration.
Corindus will also host an educational breakfast symposium “Transforming robotics into an advanced clinical tool through automation and rRemote capabilities” on Friday 27 September, chaired by Corindus’ chief medical officer, J Aaron Grantham. It will feature presentations from experts in robotic-assisted coronary intervention. Attendees will also be able to participate in a Q&A session with the faculty. Symposium topics and speakers include:
- “Clinical review” presented by Ehtisham Mahmud
- “Robotics in clinical practice: Complex PCI” presented by William Lombardi
- “Preparing for a remote PCI programme today” presented by Jean Fajadet
- “Progress on automation & remote” presented by Tejas Patel.
“My peers in the field have an appreciation for emerging treatment modalities that advance the standard of care, and we are excited to share the latest developments in robotic-assisted procedures with them,” Grantham said. “As more hospitals and health systems adopt robotic technology, it will be critical for physicians to see CorPath GRX in action and learn the benefits of the device for patients and practitioners through hands-on experience.”
